DV
Dividend Vision

SUPN — Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. (SUPN)

Total return is 798.9% over the past 14.3 years, 192.0 points ahead of SPY at 606.9%. Its deepest 1-year drawdown was 24.1%.

Supernus Pharmaceuticals, Inc. is a healthcare equity stock that focuses on pharmaceutical development and commercialization rather than functioning as a diversified ETF. As a single-stock holding with no dividend distribution rate, it does not generate ongoing income through regular distributions. This security appeals primarily to growth-oriented investors seeking exposure to the pharmaceutical sector rather than to income-focused dividend investors.

SUPN key facts

Asset type
Stock
Asset class
Equity
Inception date
05/01/2012
Distribution frequency
None
Last close
$48.27
Market cap
$2,807,769,344
Average volume
331700.0
Beta
0.56
Payout ratio
0.0
Forward P/E
20.1613
EPS
$-1.92